Classification
- Anatomical main groupJAnti-infectives for systemic use
- Therapeutic subgroupJ07
- Pharmacological subgroupJ07B
- Chemical subgroupJ07BM
- Chemical substanceJ07BM01Papillomavirus (human types 6, 11 ,16 ,18)
Where it is registered
Each register with its number of medicines and a few of them.
All medicines with Human papillomavirus vaccine
Every register, a page at a time. Strengths and packs are on each medicine’s page.
15 results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Cervarix | European Union | Authorised | GlaxoSmithKline Biologicals S.A. | ||
| Gardasil | European Union | Authorised | Merck Sharp & Dohme B.V. | ||
| Gardasil 9 | United States | 0.5ML | Injection | Marketed | Merck Sharp & Dohme LLC |
| Gardasil 9 | United States | 0.5ML | Injection | Marketed | Merck Sharp & Dohme LLC |
| CervarixCombination | United States | 0.5ML | Injection | Not marketed | GlaxoSmithKline Biologicals |
| GardasilCombination | United States | 120MCG L1 PROTEIN FROM HPV 6, 11, 16 AND 18 UG/.5ML | Injection | Not marketed | Merck Sharp & Dohme LLC |
| Silgard | European Union | Withdrawn | Merck Sharp Dohme Ltd | ||
| Gardasil™ Vaccine Vial | Singapore | 40 mcg + 40 mcg + 20 mcg + 20 mcg | solution, sterile | Authorised | MSD Pharma (Singapore) Pte. LTD. |
| Gardasil™ Vaccine Syringe | Singapore | 40 mcg + 40 mcg + 20 mcg + 20 mcg | solution, sterile | Authorised | MSD Pharma (Singapore) Pte. LTD. |
| Gardasil 9 | European Union | Authorised | Merck Sharp & Dohme B.V. | ||
| Gardasil 9Combination | New Zealand | Inj 270 mcg in 0.5 ml syringe | Funded | ||
| Cervarix Vaccine | Saudi Arabia | Authorised | Glaxosmithkline (GSK) | ||
| Cervarix Vaccine | Saudi Arabia | Authorised | Glaxosmithkline (GSK) | ||
| Cervarix Vaccine | Saudi Arabia | Authorised | Glaxosmithkline (GSK) | ||
| Gardasil Recombinant VaccineCombination | Saudi Arabia | Authorised | Merck Sharp and Dohme LLC |